Monday, October 5, 2026

Orkes Closes Series B With Same Investors Who Backed Its 2024 Series A

Orkes, an AI workflow orchestration platform, raised a Series B in April 2026. Vertex Ventures US, Nexus Venture Partners, Prosperity7 Ventures, and Naveo Commerce all returned from its 2024 Series A. Repeat investor participation at a higher round signals institutional conviction in the orchestration layer as enterprise AI automation infrastructure.

LM Salvado

April 26, 2026

Orkes Closes Series B With Same Investors Who Backed Its 2024 Series A
Image generated by AI for illustrative purposes. Not actual footage or photography from the reported events.
Loading stream...

Orkes secured a Series B in April 2026, with the same core investor group that backed its 2024 Series A returning for the follow-on round.1

Vertex Ventures US, Nexus Venture Partners, Prosperity7 Ventures, and Naveo Commerce all participated in both rounds.1 Repeat participation across consecutive rounds is a strong signal: existing investors had full information on performance and still chose to double down.

Orkes builds workflow orchestration infrastructure for enterprise AI automation. Its platform manages the sequencing, state, and error-handling of complex AI workflows — the connective tissue that makes multi-step AI systems reliable at scale.1

Orchestration has become a critical layer in enterprise AI stacks. As companies move from isolated AI models to automated pipelines, they need infrastructure that coordinates tasks, handles failures gracefully, and provides visibility into what's running. Orkes competes in this space alongside platforms like Temporal and Apache Airflow, targeting developers building production AI systems.

The back-to-back investment rounds follow a pattern seen across infrastructure layers in previous platform shifts. When cloud computing scaled, investors concentrated capital in companies building deployment and management tooling. The current AI wave is producing the same dynamic one layer up — at the workflow and orchestration level.

Sustained capital flow into this category is likely to precede consolidation.1 Larger enterprise software vendors and hyperscalers have clear strategic incentives to acquire orchestration platforms rather than build from scratch. A well-capitalized independent player with proven investor conviction becomes a natural M&A target.

For enterprises evaluating AI automation vendors, the funding trajectory of orchestration platforms matters beyond the product roadmap. It signals which infrastructure bets institutional capital considers durable — and which players are likely to be around to support long-term deployments.

About this analysis

This is a Via News analysis. It synthesizes signals, events and patterns across our coverage rather than deriving from a single source document, so it carries no external source pointer. Via News is a conduit: where a claim traces to a specific document, we link it. How we source

LM Salvado

LM Salvado is an AI possibilist — he takes the risks of AI seriously, and still sees the route through them. Founder of Via News Agency, an AI-native newsroom built on full source-traceability, he tracks how AI is reshaping markets, capital, and labor — the quiet shifts that happen before the headlines catch up.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Pharma Pipeline Catalysts and M&A Heat Up as AI-Designed Drugs Enter the Clinic
Late-September 2026 brought a dense run of clinical readouts: Novo Nordisk's CagriSema data at EASD, Lilly's ADtouch results for EBGLYSS, and Merck's tulisokibart Phase 2b result. Lilly's $2.9B Merida Biosciences acquisition and the 2026-11-14 FDA PDUFA date for ivonescimab sit alongside these as the main deal and regulatory events. AI-designed drugs such as rentosertib, and speculative AI-linked trial ventures such as QAIAx, are moving from hype toward clinical validation. Broader AI-sector regulatory and legal friction (Tesla Cybercab probe, xAI Minnesota ruling, OpenAI lawsuits) shows rising scrutiny that could spill into AI-driven healthcare.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,985
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,985 facts checked against source5,340 source documents archived
Query this data → isubstrate.com